[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"zoster\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:zoster":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100643497",false,"NCT07636044","Reduced Vaccine Response to HZ\u002Fsu in SLE","Reduced Cell-mediated Immune Response to 2 Doses of an Adjuvanted Herpes Zoster Subunit Vaccine in Patients With Systemic Lupus Erythematosus","Inclusion Criteria:\n\n* Males or females ≥ 50 years of age at time of consent\n* ≥ 4 of the 1997 ACR13 or the 2012 SLICC\u002FACR criteria for SLE (14, 15)\n* Clinically stable SLE\n* Stable dose of one or more of the following immunosuppressive treatment ≥ 4 weeks\n* Corticosteroid use: ≥ 5mg\u002Fday of prednisolone equivalent\n* Antimalarials (≤ 400 mg\u002Fday)\n* Azathioprine (≤ 3 mg\u002Fkg\u002Fday)\n* Mycophenolate mofetil (≤ 3 mg\u002Fday)\n* Tacrolimus (≤ 5mg\u002Fday)\n* Methotrexate (≤ 20mg\u002Fweek)\n* Cyclosphosphamide (≤ 1mg\u002FBSA\u002Fmonth)\n* Must be eligible for the indication of adjuvanted herpes zoster subunit vaccine\n* Must understand and voluntarily sign an informed consent form including writing consent for data protection\n\nExclusion Criteria:\n\n* Pregnant or lactating females\n* Acute infection with temperature \\>38C at the time of vaccination\n* Previous anaphylactic response to vaccine components or to egg\n* History of Guillain-Barre syndrome or demyelinating syndromes\n* Any condition including laboratory abnormality which places the subject at unacceptable risk\n* Subjects who decline to participate",true,"ALL","50 Years",{"count":19,"type":20},80,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to compare the vaccine response to the 2 doses of the adjuvanted herpes zoster subunit vaccine(HZ\u002Fsu, \"Shingrix\") in patients with SLE and the age-, sex-, ethnicity-matched controls without autoimmune disease.",[24,25,26],"Vaccine Reaction","Zoster","Systemic Lupus Erythematosus","RECRUITING","2026-06-04",{"date":30,"type":31},"2026-06-09","ACTUAL",{"date":33,"type":31},"2024-10-01",{"date":35,"type":20},"2030-10-01",{"name":37,"class":38},"Seoul National University Hospital","OTHER",""]